InnovAge (INNV) Q3 2025 earnings summary

Executive summary

• Revenue grew 13% year-over-year to $218.1 million, with participant census up 10% to approximately 7,530 across 20 centers in six states.

• Adjusted EBITDA rose to $10.8 million (4.9% margin), up from $3.0 million (1.5%) year-over-year, reflecting improved operational efficiency.

• Net loss widened to $11.1 million from $6.2 million year-over-year, impacted by higher costs and a $10.7 million legal settlement accrual.

• Operational transformation initiatives and in-house pharmacy integration drove cost discipline and improved outcomes.

• Continued investment in compliance, technology, and expansion, including acquisitions and new joint ventures.

Financial highlights

• Total revenue: $218.1 million, up 13% year-over-year and 4.4% sequentially.

• Adjusted EBITDA: $10.8 million (4.9% margin), up from $3.0 million (1.5%) year-over-year.

• Net loss: $11.1 million, compared to $6.2 million loss in prior year quarter.

• Center-level Contribution Margin: $40.7 million (18.7% of revenue), up from $34.0 million (17.6%).

• Cash and equivalents: $60.5 million; short-term investments: $41.3 million; debt: $77.3 million.

Outlook and guidance

• Fiscal 2025 guidance reaffirmed: revenue $815–$865 million; adjusted EBITDA $24–$31 million; census 7,300–7,750.

• DeNovo center losses projected at $18–$20 million for fiscal 2025.

• Guidance remains conservative due to risk score true-up variability and macroeconomic risks.

• Ongoing initiatives to offset rising costs include clinical and operational value programs and pharmacy expansion.